Tevogen Bio Holdings Inc. Stock

Equities

TVGN

US88165K1016

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-14 pm EDT 5-day change 1st Jan Change
0.92 USD -8.00% Intraday chart for Tevogen Bio Holdings Inc. -7.12% -91.73%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2022 - Sales 2023 - Capitalization 151M
Net income 2022 -22M Net income 2023 -60M EV / Sales 2022 -
Net Debt 2022 34.52M Net Debt 2023 94.37M EV / Sales 2023 -
P/E ratio 2022
-11.8 x
P/E ratio 2023
-4.56 x
Employees 19
Yield 2022 *
-
Yield 2023
-
Free-Float 3.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day-8.00%
1 week-7.12%
Current month-8.00%
1 month-62.45%
3 months-79.60%
6 months-91.56%
Current year-91.73%
More quotes
1 week
0.90
Extreme 0.9
1.48
1 month
0.80
Extreme 0.803
2.42
Current year
0.80
Extreme 0.803
21.09
1 year
0.80
Extreme 0.803
21.09
3 years
0.80
Extreme 0.803
21.09
5 years
0.80
Extreme 0.803
21.09
10 years
0.80
Extreme 0.803
21.09
More quotes
Date Price Change Volume
24-05-14 0.92 -8.00% 1,586,702
24-05-13 1 +1.57% 21,129,702
24-05-10 0.9845 -0.70% 2,396,307
24-05-09 0.9914 -0.86% 134,502
24-05-08 1 +0.96% 87,615

Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT

More quotes
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW